# Correction: Yagolovich et al. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma. Int. J. Mol. Sci. 2022, 23, 12687

**Authors:** Anne V. Yagolovich, Alina A. Isakova, Artem A. Artykov, Yekaterina V. Vorontsova, Diana V. Mazur, Nadezhda V. Antipova, Marat S. Pavlyukov, Mikhail I. Shakhparonov, Anastasia M. Gileva, Elena A. Markvicheva, Ekaterina A. Plotnikova, Andrey A. Pankratov, Mikhail P. Kirpichnikov, Marine E. Gasparian, Dmitry A. Dolgikh

PMC · DOI: 10.3390/ijms25105334 · International Journal of Molecular Sciences · 2024-05-14

## Full-text entities

- **Genes:** TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, TNFRSF10B (TNF receptor superfamily member 10b) [NCBI Gene 8795] {aka CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2}
- **Diseases:** Tumor (MESH:D009369), Glioblastoma (MESH:D005909)
- **Chemicals:** iRGD Peptide (MESH:C569656)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11121346/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11121346/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11121346/full.md

---
Source: https://tomesphere.com/paper/PMC11121346